Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Towa Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Luye Pharma Files NDA for Rivastigmine Patch in Japan for Alzheimer's
Details : Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Product Name : Rivastigmine MD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2024
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Towa Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Zai Lab Accepts Priority Review for Efgartigimod Alfa Injection in CIDP in China
Details : Vyvgart is a subcutaneous formulation of efgartigimod alfa, a human IgG1 antibody fragment. It is being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy.
Product Name : Vyvgart Hytrulo
Product Type : Antibody
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPL-01 is an extended-release injectable formulation of Naropin® (ropivacaine hydrochloride), which is a member of the amino amide class of local anesthetics indicated for the production of local or regional anesthesia for surgery and acute pain managem...
Product Name : CPL-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Neumentum
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
Product Name : NTM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Neumentum
Deal Size : Inapplicable
Deal Type : Inapplicable
Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial
Details : GV-971 (sodium oligomannate), demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well-tolerated.
Product Name : GV-971
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Product Name : Rivalif
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.
Product Name : E-58425
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rivalif (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is being developed for the treatment of mild to moderate Alzheimer's Disease.
Product Name : Rivalif
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s...
Product Name : GV-971
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2020